Tarrytown, NY, United States of America

Jonas Nielsen

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2023-2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Jonas Nielsen in Liver Disease Treatment

Introduction

Jonas Nielsen is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of medicine, particularly in the treatment of liver diseases. With a total of 2 patents to his name, his work is paving the way for new therapeutic approaches.

Latest Patents

Nielsen's latest patents focus on the treatment of liver diseases using cell death inducing DFFA like effector B (CIDEB) inhibitors. The present disclosure provides methods of treating subjects with liver disease, as well as methods for identifying individuals at an increased risk of developing such conditions. These innovative approaches highlight his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Jonas Nielsen is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to work on groundbreaking research. His role at this esteemed company allows him to collaborate with other talented professionals in the field, further enhancing his contributions to medical innovation.

Collaborations

Some of his notable coworkers include Aris I Baras and Olukayode Sosina. Their collaborative efforts contribute to the success of the projects they undertake, fostering an environment of innovation and discovery.

Conclusion

Jonas Nielsen's work in the treatment of liver diseases exemplifies the impact of innovative thinking in medicine. His patents and ongoing research are crucial in addressing significant health challenges, ultimately benefiting patients and the medical community alike.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…